A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93019D00031-0-759302300004-1
Grant search
Key facts
Disease
DengueStart & end year
20232025Known Financial Commitments (USD)
$3,096,871Funder
National Institutes of Health (NIH)Principal Investigator
ASSOCIATE PROFESSOR Anna DurbinResearch Location
United States of AmericaLead Research Institution
JOHNS HOPKINS UNIVERSITYResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Phase 2 clinical trialSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IIBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
To support a phase two clinical trial to evaluate a dengue vaccine candidate.